About Peanut Allergy
Peanut allergy is a rapidly growing problem in Australia and around the world. About one person in every fifty is allergic to peanuts, and many go on to suffer a serious, potentially life-threatening reaction to peanuts which cannot be predicted or prevented. Fatalities are fortunately rare, but allergy sufferers live in constant fear of an accidental peanut encounter.
Normally, our immune system does not react to peanuts when we are exposed to them. However, in people that suffer from peanut allergy, the immune system recognises peanuts as potentially dangerous which triggers an immune response. This response can lead to a range of symptoms, from mild itchiness, rash, and gastrointestinal upset to life-threatening anaphylaxis, with swelling and blockage of the airways and critically low blood pressure.
Aravax uses proprietary technology to precisely reset the immune system to tolerate allergens without evoking allergic reactions during treatment. The company is headquartered in Melbourne, Australia.
Following successful Phase 1 trials, Aravax's lead product PVX108 has received FDA clearance to commence Phase 2 clinical trials in the United States. PVX108 is being developed to become the first safe and convenient treatment for peanut allergy.
Aravax was founded in May 2015 through acquisition of intellectual property developed by Alfred Health and Monash University, and investment from the Medical Research Commercialisation Fund.